Calidi Biotherapeutics Inc. Cash Flow-to-Debt Ratio
Calidi Biotherapeutics Inc. cash flow-to-debt ratio. Calidi Biotherapeutics Inc. (CLDI) has a Cash Flow-to-Debt Ratio of -0.99x as of December 2025, meaning its operating cash flow of $-5.04 Million could theoretically repay -1% of its total liabilities ($5.10 Million) in one year. See Calidi Biotherapeutics Inc. financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Calidi Biotherapeutics Inc. (2020–2025)
Cash flow-to-debt ratio of Calidi Biotherapeutics Inc. from 2020 to 2025. Historical debt coverage capacity for Calidi Biotherapeutics Inc. across 6 annual periods. See CLDI net asset quality index to measure how much of total assets are equity-financed.
Calidi Biotherapeutics Inc. Cash Flow-to-Debt Ratio by Year (2020–2025)
Calidi Biotherapeutics Inc. cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Calidi Biotherapeutics Inc.. For the full cash flow conversion analysis, see CLDI cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.18x | $-21.29 Million | $5.10 Million | ▼ -159.0% |
| 2024 | -1.61x | $-19.69 Million | $12.21 Million | ▼ -9.1% |
| 2023 | -1.48x | $-26.98 Million | $18.25 Million | ▼ -493.3% |
| 2022 | -0.25x | $-13.21 Million | $53.04 Million | ▲ +16.7% |
| 2021 | -0.30x | $-7.77 Million | $26.00 Million | ▼ -50.7% |
| 2020 | -0.20x | $-4.83 Million | $24.33 Million | — |